Shigeki Seto

733 citations

25 papers · 578 indexed · h-index 12

Co-authors: Hiroyuki Kakei Porino Va David A. Colby Hayato Ishikawa Thomas J. Rayl Inkyu Hwang Dale L. Boger Annie Tam
Topics: Chemical synthesis and alkaloids (5 papers)Synthesis of heterocyclic compounds (4 papers)Alkaloids: synthesis and pharmacology (4 papers)
Cited by: Organic Chemistry Pharmacology Pharmaceutical Science
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Tetrahedron
Partner nations: Japan United States Australia

In The Last Decade

Shigeki Seto

25 papers receiving 559 citations

Peers

Countries citing papers authored by Shigeki Seto

Since Specialization

Citations

This map shows the geographic impact of Shigeki Seto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeki Seto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeki Seto more than expected).

Fields of papers citing papers by Shigeki Seto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeki Seto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeki Seto. The network helps show where Shigeki Seto may publish in the future.

Co-authorship network of co-authors of Shigeki Seto

This figure shows the co-authorship network connecting the top 25 collaborators of Shigeki Seto. A scholar is included among the top collaborators of Shigeki Seto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeki Seto. Shigeki Seto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model 2021 ·Bioorganic & Medicinal Chemistry ·Masanori Sato,(unknown),Yasushi Kohno,Shigeki Seto	6
2	Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP1 receptor antagonists 2017 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),(unknown),Yasushi Kohno,Nobuyuki Tanaka,Shigeki Seto	3
3	Novel pyrazolo[1,5-a]pyridines as orally active EP1 receptor antagonists: Synthesis, structure-activity relationship studies, and biological evaluation 2017 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),Nobuyuki Tanaka,Yasushi Kohno,Shigeki Seto	20
4	Discovery of novel pyrazolo[1,5-a]pyridine-based EP1 receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Yoshifumi Saito,Hiroyuki Watanabe,(unknown),(unknown),Naohiro Kawamura,(unknown),Yasushi Kohno,Nobuyuki Tanaka,Shigeki Seto	15
5	Synthesis of 2-Arylpyrazolo[1,5-a]pyridines by Suzuki–Miyaura Cross-Coupling Reaction 2015 ·Synthesis ·Shigeki Seto,(unknown),(unknown),(unknown),Yasushi Kohno	5
6	Synthesis and structure–activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Bei Li,Tyzoon Nomanbhoy,Qiang Li,Ayako Nakamura,(unknown),Masahiro Nomura,Kyoko Okada,Shigeki Seto,(unknown),Marek Liyanage,(unknown),Arwin Aban,(unknown),Anna Katrin Szardenings,Jonathan S. Rosenblum,John W. Kozarich,Yasushi Kohno,Kevin Shreder	20
7	Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics 2011 ·Bioorganic & Medicinal Chemistry ·Shigeki Seto,Kazuhiko Yumoto,Kyoko Okada,Y. Asahina,Aya Iwane,(unknown),(unknown),Kevin Shreder,(unknown),Yasushi Kohno	18
8	Design, Synthesis, and Structure−Activity Relationship Studies of Novel 2,4,6-Trisubstituted-5-pyrimidinecarboxylic Acids as Peroxisome Proliferator-Activated Receptor γ (PPARγ) Partial Agonists with Comparable Antidiabetic Efficacy to Rosiglitazone 2010 ·Journal of Medicinal Chemistry ·Shigeki Seto,Kyoko Okada,(unknown),(unknown),(unknown),(unknown),Yoshiaki Kitamura,Yasushi Kohno,Koji Murakami	16
9	Synthesis of Vinblastine 2009 ·Synfacts ·H. Ishikawa,Denise A. Colby,Shigeki Seto,Porino Va,Arvin B. Tam,Hiroyuki Kakei,Thomas J. Rayl,Inkyu Hwang,Dale L. Boger	1
10	Total Synthesis of Vinblastine, Vincristine, Related Natural Products, and Key Structural Analogues 2009 ·Journal of the American Chemical Society ·Hayato Ishikawa,David A. Colby,Shigeki Seto,Porino Va,Annie Tam,Hiroyuki Kakei,Thomas J. Rayl,Inkyu Hwang,Dale L. Boger	294
11	Chemoselective Displacement of Methylsulfinyl Group with Amines to Provide 2-Alkylamino-4,6-disubstituted Pyrimidine-5-carboxylic Acid 2009 ·Heterocycles ·Shigeki Seto,Yasushi Kohno	3
12	Analysis of crucial structural requirements of 2-substituted pyrimido[4,5-b][1,5]oxazocines as NK1 receptor antagonist by axially chiral derivatives 2007 ·Bioorganic & Medicinal Chemistry ·Shigeki Seto,Jun Asano	10
13	Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists 2005 ·Bioorganic & Medicinal Chemistry ·Shigeki Seto,(unknown),Makoto Ikeda,(unknown)	30
14	Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 antagonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Shigeki Seto,(unknown),Makoto Ikeda,(unknown)	22
15	2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist 2005 ·Bioorganic & Medicinal Chemistry Letters ·Shigeki Seto,(unknown),Makoto Ikeda,(unknown)	18
16	Convenient synthesis of 7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,5-b]- and [2,3-b]-1,5-oxazocine-6-ones 2004 ·Tetrahedron Letters ·Shigeki Seto	14
17	Novel Seco Cyclopropa[c]pyrrolo[3,2-e]indole Bisalkylators Bearing a 3,3‘-Arylenebisacryloyl Group as a Linker 2001 ·Journal of Medicinal Chemistry ·Yasumichi Fukuda,Shigeki Seto,(unknown),(unknown),(unknown),Shiro Terashima	35
18	The novel cyclopropapyrroloindole(CPI) bisalkylators bearing 3,3′-(1,4-phenylene)diacryloyl group as a linker 1998 ·Bioorganic & Medicinal Chemistry Letters ·Yasumichi Fukuda,Shigeki Seto,(unknown),(unknown),(unknown),Shiro Terashima	15
19	Cyclopropapyrroloindole (CPI) bisalkylators 1998 ·Drugs of the Future ·Yoshiyuki Fukuda,Shigeki Seto,H. Furuta,(unknown),(unknown),S. TERASHIMA	1
20	A Straightforward Preparation of Chiral 5-(Aminomethyl)oxazole Derivatives from .ALPHA.-Amino Esters and .ALPHA.-Lithiated Isocyanides. 1998 ·Chemical and Pharmaceutical Bulletin ·Masashi Ohba,Hiroyuki Kubo,Shigeki Seto,Tozo Fujii,Hiroyuki Ishibashi	11

About Shigeki Seto

Shigeki Seto is a scholar working on Organic Chemistry, Pharmacology and Pharmacology, having authored 25 papers that have together received 578 indexed citations. Recurring topics across this work include Chemical synthesis and alkaloids (5 papers), Synthesis of heterocyclic compounds (4 papers) and Alkaloids: synthesis and pharmacology (4 papers). The work is most often cited by research in Organic Chemistry (409 citations), Pharmacology (92 citations) and Pharmaceutical Science (37 citations). Shigeki Seto has collaborated with scholars based in Japan, United States and Australia. Frequent co-authors include Hiroyuki Kakei, Porino Va, David A. Colby, Hayato Ishikawa, Thomas J. Rayl, Inkyu Hwang, Dale L. Boger, Annie Tam, Makoto Ikeda and Yasushi Kohno. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Tetrahedron.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact